Global X Cybersecurity vs Charles River Laboratories Intl. Inc — how do they compare? Global X Cybersecurity trades at $42.42, while Charles River Laboratories Intl. Inc trades at $228.98 (market cap $11.14B). Which is the better fit depends on your goals.
| BUG | CRL | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $41.99 | $233.60 |
52-Week Low | $23.30 | $145.57 |
Market Cap | — | $11.14B |
Enterprise Value | — | $14.00B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Trailing returns across standard periods
Latest headlines on both assets
BUG is a thematic ETF that invests in companies at the forefront of the global cybersecurity industry. It provides concentrated exposure to leaders in network security, endpoint protection, and cloud security, such as Fortinet, Akamai, and CrowdStrike.
Read more on BUG →Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →